Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment, Genetics and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal.
Center for Innovative Biomedicine and Biotechnology (CIBB), University of Coimbra, 3000-548 Coimbra, Portugal.
Int J Mol Sci. 2022 Aug 2;23(15):8570. doi: 10.3390/ijms23158570.
The increasing cancer incidence has certified oncological management as one of the most critical challenges for the coming decades. New anticancer strategies are still needed, despite the significant advances brought to the forefront in the last decades. The most recent, promising therapeutic approaches have benefitted from the application of human perinatal derivatives (PnD), biological mediators with proven benefits in several fields beyond oncology. To elucidate preclinical results and clinic outcomes achieved in the oncological field, we present a narrative review of the studies resorting to animal models to assess specific outcomes of PnD products. Recent preclinical evidence points to promising anticancer effects offered by PnD mediators isolated from the placenta, amniotic membrane, amniotic fluid, and umbilical cord. Described effects include tumorigenesis prevention, uncontrolled growth or regrowth inhibition, tumor homing ability, and adequate cell-based delivery capacity. Furthermore, PnD treatments have been described as supportive of chemotherapy and radiological therapies, particularly when resistance has been reported. However, opposite effects of PnD products have also been observed, offering support and trophic effect to malignant cells. Such paradoxical and dichotomous roles need to be intensively investigated. Current hypotheses identify as explanatory some critical factors, such as the type of the PnD biological products used or the manufacturing procedure to prepare the tissue/cellular treatment, the experimental design (including human-relevant animal models), and intrinsic pathophysiological characteristics. The effective and safe translation of PnD treatments to clinical practice relies on the collaborative efforts of all researchers working with human-relevant oncological preclinical models. However, it requires proper guidelines and consensus compiled by experts and health workers who accurately describe the methodology of tissue collection, PnD isolation, manufacturing, preservation, and delivery to the final user.
癌症发病率的不断增加,已使肿瘤学管理成为未来几十年最关键的挑战之一。尽管过去几十年取得了重大进展,但仍需要新的抗癌策略。最近,有希望的治疗方法得益于应用人类围产期衍生物(PnD),这些生物介质在肿瘤学以外的多个领域已被证明具有益处。为了阐明在肿瘤学领域取得的临床前结果和临床结果,我们对利用动物模型评估 PnD 产品特定结果的研究进行了叙述性综述。最近的临床前证据表明,从胎盘、羊膜、羊水和脐带中分离出的 PnD 介质具有有前途的抗癌作用。描述的作用包括肿瘤发生预防、失控生长或再生长抑制、肿瘤归巢能力和适当的基于细胞的输送能力。此外,已经描述了 PnD 治疗方法对化疗和放射治疗具有支持作用,特别是在报告出现耐药性时。然而,也观察到了 PnD 产品的相反作用,为恶性细胞提供支持和营养作用。这种矛盾和二分法的作用需要深入研究。目前的假设认为,一些关键因素可以解释这种现象,例如使用的 PnD 生物产品的类型或制备组织/细胞治疗的制造程序、实验设计(包括与人相关的动物模型)以及内在的病理生理特征。将 PnD 治疗方法有效地安全地转化为临床实践,依赖于所有使用与人相关的肿瘤学临床前模型的研究人员的合作努力。然而,这需要由专家和卫生工作者编写的适当指南和共识,准确描述组织收集、PnD 分离、制造、保存和最终用户交付的方法。